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ABSTRACT
A variety of compounds will distribute into the brain when placed
at the cribriform plate by intranasal (i.n.) administration. In this
study, we investigated the ability of albumin, a protein that can
act as a drug carrier but is excluded from brain by the blood-
brain barrier, to distribute into the brain after i.n. administration.
We labeled bovine serum albumin with [125I] ([125I]Alb) and studied
its uptake into 11 brain regions and its entry into the blood from
5minutes to 6 hours after i.n. administration. [125I]Alb was present
throughout the brain at 5 minutes. Several regions showed
distinct peaks in uptake that ranged from 5 minutes (parietal
cortex) to 60 minutes (midbrain). About 2–4% of the i.n. [125I]Alb
entered the bloodstream. The highest levels occurred in the
olfactory bulb and striatum. Distribution was dose-dependent,
with less taken up by whole brain, cortex, and blood at the higher
dose of albumin. Uptake was selectively increased into the
olfactory bulb and cortex by the fluid-phase stimulator PMA
(phorbol 12-myristate 13-acetate), but inhibitors to receptor-
mediated transcytosis, caveolae, and phosphoinositide 3-kinase
were without effect. Albumin altered the distribution of radioac-
tive leptin given by i.n. administration, decreasing uptake into
the blood and by the cerebellum and increasing uptake by the
hypothalamus. We conclude that [125I]Alb administered i.n.
reaches all parts of the brain through a dose-dependent mech-
anism that may involve fluid-phase transcytosis and, as illustrated
by leptin, can affect the delivery of other substances to the brain
after their i.n. administration.
Introduction
Drug delivery to the brain for the treatment of a wide
variety of diseases is hampered by the blood-brain barrier
(BBB). In recent years, intranasal (i.n.) administration has
come to light as an effective and noninvasive means to
circumvent the BBB for a variety of substances, including
polypeptides, liposomes, virus vectors for gene therapy, and
stem cells (Dhuria et al., 2010; Lochhead and Thorne,
2012a). These substances not only reach the brain tissue,
but bioactive compounds such as insulin (Reger et al., 2008;
Benedict et al., 2011; Craft et al., 2012), oxytocin (Veening
and Olivier, 2013), and leptin (Schulz et al., 2012) do so in
levels sufficient to cause significant behavioral changes in
both patients and animal models of disease.
Albumin, the pre-eminent transport protein in the blood, is
emerging as a versatile transport molecule for targeted drug
delivery (Kratz, 2008), and albumin has recently gained attention
in the field of pharmaceutical development for its ability to pro-
long the half-life and stability of bioactive compounds (Elsadek
and Kratz, 2012). Whereas albumin binding proteins, such as
gp60 (albondin), facilitate transcytosis of albumin in peripheral
capillaries, there is low expression in brain endothelial cells
(Schnitzer, 1992), and albumin has been shown not to cross the
BBB in vivo or in vitro (Pardridge et al., 1985); however, a study
has suggested that ovalbuminmay be taken up by brain after i.n.
administration (Migliore et al., 2010).
Here, we assessedwhether i.n. administration of radioactively
labeled albumin in CD1mice is an effectivemethod of delivery to
the brain. We also examined the regional distribution and time
course of administered albumin, explored the cellular mecha-
nisms of brain uptake, and assessed i.n. albumin’s effect on
distribution of another potential central nervous system (CNS)
therapeutic, leptin.
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Materials and Methods
Animals. Male CD1 mice, 8 weeks of age, purchased from Charles
River Laboratories (Wilmington, MA), were used throughout these
experiments. Mice had free access to food and water and were on a
12-hour light/dark cycle. All studies were performed under approved
Institutional Animal Care and Use Committee protocols and by an
Association for Assessment and Accreditation of Laboratory Animal
Care International accredited facility.
Iodination of Albumin and Leptin. Bovine serum albumin
(BSA) (Sigma-Aldrich, St. Louis, MO) andmurine leptin (R&D Systems
Inc., Minneapolis, MN) were radioactively labeled with [125I] by
the chloramine-T method (Greenwood et al., 1963). Briefly, 10 mg of
albumin [1 mg/ml in 0.25 M phosphate buffer (PB)] or 5 mg of leptin
(1 mg/ml in dIH2O) was labeled with 0.5 mCi of [
125I] (PerkinElmer,
Waltham, MA). The BSA was purified on a column of Sephadex G-10
(GE Healthcare, Piscataway, NJ) and the leptin on a Nap-5 column
Sephadex G-25 DNA grade (GE Healthcare). The BSA fractions were
collected at 1-minute intervals into 100 ml lactated Ringer’s solution
(LR; Baxter International, Deerfield, IL) in glass tubes treated with
Sigmacote siliconizing reagent (Sigma-Aldrich); the leptin fractions
were collected in plastic tubes at 1-minute intervals into 100 ml of LR
solution with or without 1% BSA. An acid precipitation using 15%
trichloroacetic acid was then performed to assess purity. The per-







Only fractions that showed.90% activity in the precipitate were used
in the experiment.
Intranasal Administration. Mice were anesthetized by i.p. in-
jection of urethane, 40% solution (Sigma-Aldrich); 1 ml containing
400,000 counts per minute (CPM) of [125I]Alb in PB was administered
i.n. via a micropipette tip inserted 4 mm into the left nostril of each
mouse. Leptin labeled with [125I] ([125I]Lep) was injected in PBwith or
without 1% BSA (1 g/100 ml) added to the PB saline vehicle.
Tissue Collections. Male CD1 mice were anesthetized and ad-
ministered i.n. [125I]Alb or [125I]Lep as described. Blood was collected
from the carotid artery, and the whole brain was removed at a
predetermined time point after i.n. administration. Time points were
5, 10, and 30 minutes, and 1, 2, 4, and 6 hours. The brain was dis-
sected using the method of Glowinski and Iversen (1966) on ice into
11 regions of the olfactory bulb, occipital cortex, striatum, frontal
cortex, hypothalamus, thalamus, hippocampus, parietal cortex,
cerebellum, midbrain, and ponsmedulla, and each region was weighed.
The collected whole blood was allowed to clot at room temperature,
centrifuged at 5400g for 10minutes at 4°C, and 50ml of resulting serum
was removed for use. The level of radioactivity in each of the 11 regions
and the serum sample was determined in aWizard2AutomaticGamma
Counter (PerkinElmer) by counting for 30 minutes. Values for the
whole brain were calculated by summing the regional weights and the
regional levels of radioactivity of all tissue samples except the olfactory
bulb. The percentage of the injected dose present in amilliliter of serum
(%Inj/ml) was calculated with the following formula (eq. 2):
%Inj=ml5 ½100 ðCPM=mlÞ=Inj; (2)
where Inj is the CPM administered and CPM/ml is the level of
radioactivity in a milliliter of serum. The percentage of the injected
dose taken up per gram of brain region (%Inj/g) was calculated at each
time with the following formula (eq. 3):
%Inj=g5 ½100 ðCPM=RÞ=InjðWÞ; (3)
where W is the weight of the given brain region in grams, and CPM/R
is the level of radioactivity in the brain region. The rate at which i.n.
[125I]Alb would have to enter into the blood to reach the levels






where T is the entry rate into blood in %Inj/min, P is the level of
[125I]Alb measured in serum in %Inj/ml at time t, Vd is volume of dis-
tribution inml, t is sampling time inminutes, andK5 (0.693/t1/2), where
t1/2 is the half-time clearance of [
125I]Alb from blood after i.v. injection.
The values used for t1/2 andVd for [
125I]Albwere 316minutes and 1.76ml
as previously measured (Banks and Broadwell, 1994).
Acid Precipitations. Male CD1 mice were anesthetized and
administered i.n. [125I]Alb as described. Blood was collected from the
external jugular vein, and the whole brain was removed at 10minutes or
at 60minutes after the i.n. administration of [125I]Alb (n5 7mice/group).
Olfactory bulb, cortex, and cerebellum were dissected from the re-
mainder of the brain on ice and collected in 1 ml of 1% BSA in LR.
Tissue samples were homogenized in a Mini-BeadBeater (BioSpec
Products, Inc., Bartlesville, OK) twice (30 seconds each pulse; 4800
rpm), then centrifuged at 10,000g for 20 minutes at 4°C. Whole blood
samples were allowed to clot at room temperature and then centrifuged
at 5400g for 10 minutes and also at 4°C. A 50-ml portion of the
supernatant from each sample was used to perform an acid pre-
cipitation using 15% trichloroacetic acid. To determine the amount of
degradation that occurred with processing, 400,000 CPM was added in
vitro to a sample of serum or a brain region obtained from amouse that
had not received i.n. [125I]Alb (n 5 2). Samples were then processed as
described. After the addition of trichloroacetic acid, the serum, brain,
and processing controls were centrifuged at 5000g for 10 minutes at
4°C, and the supernatant was separated from the pellet. The
radioactivity of both pellet and supernatant was determined in
a Wizard2 Automatic Gamma Counter (PerkinElmer) by counting
for 30 minutes, and the percentage of radioactivity precipitated






The percentage that was precipitated from samples was divided by
that which precipitated in the processing controls and multiplied by
100 to give an index of intact [125I]Alb.
[125I]Alb versus [125I]Alb 1 Unlabeled Albumin. Male CD1
mice were anesthetized as described above and administered i.n.
[125I]Alb with or without 10 mg (2 mg/ml in PB) of unlabeled albumin
(n5 29/group). Blood was collected from the external jugular vein, and
the whole brain was removed 30 minutes after the i.n. administra-
tion. Olfactory bulb, cortex, and cerebellum were dissected from the
remainder of the brain on ice; each region was weighed; and the level
of radioactivity was determined in a Wizard2 Automatic Gamma
Counter by counting for 30 minutes. Whole brain mass and ra-
dioactivity were determined by combining the mass and radioactivity
of all regions except the olfactory bulb. Whole blood was allowed to
clot at room temperature and centrifuged at 5400g for 15 minutes at
4°C, and the radioactivity of 50 ml of the resulting serum was counted
for 30 minutes.
Modifiers of Cellular Mechanisms of Uptake. Male CD1 mice
were anesthetized as described herein and administered i.n. a 1-ml
solution containing various substances known to alter physiologic
pathways of transport. The concentrations chosen for use in this study
were based on concentrations available in the literature for use of
these substances in vivo. For substances for which in vivo data are not
available, the in vitro concentrations were used since i.n. adminis-
tration is considered an in situ model. These substances include
phenylarsine oxide [100 mM in dimethylsulfoxide (DMSO); n 5 14],
filipin (5 mg/ml in DMSO; n 5 15), LY294002 [2-(4-morpholinyl)-8-
phenyl-1(4H)-benzopyran-4-one hydrochloride] (50 mM in DMSO; n5
15), PMA (phorbol 12-myristate 13-acetate) (100 ng/ml in DMSO; n5
15), histamine [100 ng/ml in methanol (MeOH); n 5 10], monensin
(50 mM in MeOH; n 5 10), verapamil (10 mM in MeOH; n 5 10), and
lidocaine (1% solution in MeOH; n 5 10) (all purchased from Sigma-
Aldrich). For controls (n 5 20), 1 ml of either DMSO or MeOH, the
vehicle used to deliver the drugs, was administered. Each drug group
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was done concurrently with a control group, and 30 minutes after
injection of an inhibitor or control (DMSO orMeOH), 1 ml of 0.25M PB
containing 400,000 CPM of [125I]Alb was administered i.n. 4 mm into
the right nostril. Blood was collected from the external jugular vein,
and the whole brain was removed 15minutes after i.n. administration
of [125I]Alb. The olfactory bulb, cortex, and cerebellum were dissected
from the remainder of the brain on ice, each region was weighed, and
the level of radioactivity determined in a Wizard2 Automatic Gamma
Counter by counting for 30 minutes. Whole brain mass and ra-
dioactivity were determined by combining the mass and radioactivity
of all regions except the olfactory bulb. Whole blood was allowed to
clot at room temperature and centrifuged at 5400g for 15 minutes at
4°C, and the radioactivity was counted in 50 ml of the resulting serum
for 30 minutes. The percentage of the injected dose present in 1 ml
of serum (%Inj/ml) and the percentage of injected dose taken up
per gram of brain region (%Inj/g) were calculated according to the
equations herein.
Statistical Analysis. Means are reported with their standard
error and number. Means were compared by two-tailed t test. Statis-
tical significance was taken as P , 0.05. The Prism 5.0 statistical soft-
ware program (GraphPad Software Inc., San Diego, CA) was used in
statistical analysis.
Results
Our first goals were to determine whether i.n.-administered
albumin reaches the brain, where in the brain it distributes,
and the time course of delivery and clearance. We therefore
harvested the brain over a 6-hour period, dividing it into the
10 regions of Glowinski and Iversen (1966) plus the olfactory
bulb. Figure 1 shows the percentage of i.n.-administered
[125I]Alb taken up by each brain region (%Inj/g) at the various
time points and the varying regional patterns of [125I]Alb uptake
and clearance.
All brain regions showed uptake of [125I]Alb at 5 minutes,
the first time point examined (Fig. 1). The highest peaks
occurred in the olfactory bulb (1.06%Inj/g 6 0.35, n 5 15) and
striatum (0.45%Inj/g 6 0.21, n 5 10). In the frontal cortex,
parietal cortex, occipital, thalamus, cerebellum, and pons me-
dulla, the concentration of [125I]Alb was highest at 5 minutes,
after which it decreased gradually. Among the three cortical
regions, the frontal cortex and occipital cortex remained steady
at 0.10–0.15%Inj/g through the first 2 hours, whereas the
parietal cortex decreased earlier, having undetectable levels by
2 hours. Several regions demonstrated distinct peaks in %Inj/g,
including the olfactory bulb at 10 minutes, the striatum at
30minutes, and the midbrain and hypothalamus at 60 minutes.
The cerebellum had the lowest peak level and was the first to
be cleared with undetectable levels 60 minutes after i.n.
administration of [125I]Alb. [125I]Alb is essentially cleared
from all regions by 4 hours.
The %Inj/ml of serum (Fig. 2) remained fairly steady at 1%
Inj/ml, trending upward at the 6-hour time point. The rate at
which [125I]Alb would enter the bloodstream to produce these
Fig. 1. Distribution in brain after i.n.
administration of [125I]Alb. Appearance of
[125I]Alb in the olfactory bulb, striatum,
frontal cortex, hypothalamus, hippocampus,
thalamus, parietal cortex, occipital cortex,
cerebellum, midbrain, pons medulla, and
whole brain at 5minutes (n = 15), 10 minutes
(n = 15), 30 minutes (n = 10), 60 minutes (n =
15), 2 hours (n = 20), 4 hours (n = 15), and
6 hours (n = 17) post–i.n. administration of
[125I]Alb. The peak valuewas at 5minutes in
the frontal cortex, parietal cortex, occipital
cortex, thalamus, cerebellum, pons medulla
and whole brain; 10 minutes in olfactory
bulb; 30 minutes in striatum and hippocam-
pus; and 60 minutes in the midbrain and
hypothalamus.
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levels ranged from about 0.32%Inj/min at 5minutes to a low of
0.012%Inj/min at 360 minutes. Multiplying time by %Inj/min
showed that about 1.5–4% of the i.n. dose of [125I]Alb entered
the blood stream during the course of the study.
To determine the extent to which the radioactivity observed
in the brain after i.n. administration of [125I]Alb accurately
represents the presence of the administered protein, we per-
formed an acid precipitation of the tissue. Because most of the
regions showed the strongest signal within the first hour, we
chose to examine time points 10 and 60 minutes after i.n.
administration. Four regions were examined, and the radio-
activity of each sample after precipitation is reported as a
percentage of a matched processing control (Table 1). When
measurements were pooled from all regions and both time
points, the mean adjusted percentage was 61.36% (6 9.40%),
representing the portion of radioactivity measured throughout
these experiments that reliably signifies intact [125I]Alb. No
statistical differences were seen in any regions between the two
time points (P . 0.05 by two-way analysis of variance).
To investigate the dose dependence of albumin uptake, we
administered 400,000 CPM of [125I]Alb with and without
additional unlabeled albumin, the results of which are shown
in Fig. 3. Inclusion of unlabeled albumin decreased [125I]Alb
uptake by the cortex (0.074 6 0.008 with unlabeled albumin
versus 0.1466 0.030 without, P, 0.05), whole brain (0.0856
0.009 with unlabeled albumin versus 0.132 6 0.017 without,
P, 0.05), and serum (2.2906 0.1759 with unlabeled albumin
versus 4.645 6 1.007 without, P , 0.05). Changes in olfactory
bulb and cerebellum were not significant.
Cellular mechanisms for [125I]Alb uptake into the brain
and blood were studied by administering agents 30 minutes
before [125I]Alb i.n. administration and harvesting brains 15
minutes after i.n. administration. The agents were phenyl-
arsine oxide, filipin, LY294002, and PMA, lidocaine, hista-
mine, monensin, and verapamil. DMSO or MeOH was used
as control, depending on the solubility of the inhibitor. Only
PMA had a statistically significant effect (Fig. 4), increasing
uptake at the olfactory bulb and cortex, but with no effect on
cerebellum, or whole brain. PMA had no effect on serum
levels, and the other agents were without effects on brain or
serum levels (data not shown).
The ability of albumin to influence brain distribution of
substances administered by the i.n. route was tested by
examining the distribution of [125I]Lep given with or without
albumin included in the i.n. injection. Figure 5 shows that
coadministration with albumin decreased [125I]Lep entry into
the blood and uptake by the cerebellum, but it increased
hypothalamic uptake. There were also statistical trends for
decreasing uptakes by the olfactory bulb and whole brain but
without an influence on hippocampus.
Discussion
Intranasal administration is a promising approach for the
delivery of biologicals to the brain (Frey, 2002; Lochhead and
Thorne, 2012b); however, it is unknown which substances can
or cannot use this route, nor is it known what cellular mech-
anisms underlie this uptake. Here, we investigated albumin
uptake after i.n. administration. If albumin were to be taken
up after i.n. administration, it might act as a binder and
carrier, helping to direct substances to specific brain regions,
similar to the role albumin plays in the circulation. Albumin is
by far the most versatile transport protein in the blood cir-
culation and has been used in a variety of pharmaceutical
applications, as has been recently reviewed (Elsadek and
Kratz, 2012). Several strategies have been developed to link
drugs, prodrugs, and bioactive polypeptides to albumin, in-
cluding various forms of physical and covalent binding as well
as drug encapsulation in albumin nanoparticles (Kratz, 2008;
Elsadek and Kratz, 2012). Levemir and Victoza, developed by
Fig. 2. Level and rate of appearance of [125I]Alb in serum after i.n.
administration. Appearance of [125I]Alb in serum at 5 minutes (n = 15),
10 minutes (n = 15), 30 minutes (n = 10), 1 hour (n = 15), 2 hours (n = 20),
4 hours (n = 15), and 6 hours (n = 17) after i.n. administration of [125I]Alb
(left y-axis). Values were steady at about 1%Inj/ml, peak value at 6 hours.
Rates of entry into serum during same time course (right y-axis).
TABLE 1
Acid precipitation of radioactivity extracted from brain regions after
intranasal administration of albumin labeled with radioactive iodine
Percentage of acid precipitation for whole brain and brain regions 10 and 60 minutes
after intranasal administration of albumin labeled with radioactive iodine. Values




10 Minutes 60 Minutes
Olfactory bulb 108 6 30 (7) 75 6 18 (6)
Cortex 62 6 19 (5) 60 6 18 (6)
Cerebellum 87 6 29 (6) 81 6 32 (5)
Whole brain 74 6 18 (6) 74 6 13 (4)
Fig. 3. Dose-dependent distribution of [125I]Alb. %Inj/g of [125I]Alb 6
unlabeled albumin in the olfactory bulb (OB), cortex (Crtx), cerebellum
(Cb), and whole brain (WB) 30 minutes after i.n. administration of
[125I]Alb. Inset shows%Inj/ml for serumat 30minutes after i.n. administra-
tion. Whole brain was calculated by combining the cerebellum, cortex, and
remainder but excluding olfactory bulb. Unlabeled albumin produced sig-
nificant decreases (*P, 0.05; n = 29) in the cortex, whole brain, and serum as
assessed by t test.
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Novo Nordisk (Bagsvaerd, Denmark) for the treatment of
diabetes, are long-lasting derivatives of human insulin and
glucagon-like peptide-1 agonist, respectively. Through the
attachment of myristic acid, a saturated fatty acid that binds
albumin with high affinity, the serum half-life of these com-
pounds is extended from minutes to hours (Elsadek and Kratz,
2012; Kratz and Elsadek, 2012). Albumin-binding moieties,
such as myristic acid, maleimide, and a growing number of
synthetic peptides, offer a simple and effectivemeans of linking
drugs to exogenous and endogenous serum albumin. Developing
albumin to play similar roles after i.n. administration could be
amajor advance in this approach for the delivery of biologicals to
the brain.
Recent reviews of i.n. administration (Dhuria et al., 2010)
make a good case for the involvement of the olfactory nerves,
noting the high turnover of olfactory neurons and the presence
of perineural channels created by olfactory ensheathing cells.
Our results are consistent with this model: whereas [125I]Alb
was seen in all regions of the brain, the highest levels by far
were seen in the olfactory bulbs. Numerous studies have noted
the rapidity with which i.n. applied substances reach tissues
distant to the nose. Most have observed the highest CNS
concentrations within the first hour, many almost immedi-
ately after administration (Dhuria et al., 2010). Here, we also
observed very rapid distribution of [125I]Alb, with measurable
amounts in all regions at 5 minutes. Recent work using both
confocal imaging (Iliff et al., 2012) and contrast-enhanced MRI
(Iliff et al., 2013) indicates that a large portion of cerebrospinal
fluid (CSF) moves into the brain by bulk flow through arterial
perivascular spaces, traverses the parenchyma, and is cleared
along venous perivascular spaces. These perivascular spaces
additionally provide a means of rapid transport of CSF within
the wider subarachnoid space. The pattern of brain [125I]Alb
uptake described here could be explained by transport from the
nasal epithelium along the olfactory nerves into the CSF, dif-
fusion into arterial perivascular spaces, and rapid distribution
throughout the brain. This explanation is supported by findings
that elevated CSF levels of i.n. administered substances precede
elevations in tissue levels (Charlton et al., 2008).
The results of the acid precipitation study suggest that the
radioactivity of [125I] in these experiments, although not an
exact measure of albumin integrity, does provide a reliable
proxy for its presence. Within 5minutes of i.n. administration,
[125I]Alb was seen to reach all regions of the brain. After this,
unique patterns of uptake and clearance emerged in different
brain regions. As for other compounds (Frey, 2002; Thorne
et al., 2004), we observed highest uptake of albumin in the
olfactory bulbs with much lower uptake in all other regions.
Many regions showed highest levels of uptake at the first time
point, after which [125I]Alb was gradually cleared. The rate
of clearance showed regional differences, but [125I]Alb was
effectively cleared from all regions by the 4-hour time point.
The striatum and midbrain exhibited distinct peaks in con-
centration, consistent with active uptake or transient seques-
tration of [125I]Alb in these regions. These patterns differ from
those seen after i.n. administration of other peptides, including
pituitary adenylate cyclase–activating polypeptide (Nonaka et al.,
2012), the angiotensin antagonist GR138950 (1-[[3-bromo-2-
[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]
methyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide)
(Charlton et al., 2008), and testosterone (Banks et al., 2009).
This variability could suggest that different molecules may
undergo unique mechanisms of uptake.
We found little [125I]Alb entering the bloodstream when
assessed either as the percentage of the injected dose that
accumulated in blood or when calculated as a transport rate.
The transport rate suggests that most entry into blood occurs
early and that less than 4% of the injected dose reaches the
bloodstream. This rate is even less than other biologicals
given by the i.n. route (Banks et al., 2004) and suggests that
coadministration with albumin may act to keep the coadmin-
istered substance within the CNS.
In these experiments, we sought to characterize the mech-
anism of albumin uptake. The decreases in [125I]Alb uptake
by whole brain and cortex seen when coadministered with
unlabeled albumin may indicate competition for a saturable
mechanism. The decrease in the [125I]Alb level in serum seen
with coadministration of unlabeled albumin supports the idea
of dose-dependent uptake. However, levels in the olfactory bulb
were not decreased, suggesting that the dose dependence may
have more to do with distribution within the CNS after initial
entry than with entry itself.
We saw that pretreatment with PMA increased the uptake of
[125I]Alb in the olfactory bulb and cortex, but not the cer-
ebellum or whole brain, suggesting a role for PKC signaling in
the active nose-to-brain transport of [125I]Alb (Wu-Zhang and
Fig. 4. Cellular mechanisms of uptake of i.n. administered [125I]Alb.
Influence of the fluid-phase stimulator PMA on the percentage of [125I]Alb
taken up per gram of tissue (%Inj/g) by the olfactory bulbs (Olf Bulb),
cortex, cerebellum, and whole brain. PMAwas given 30 minutes before i.n.
administration of [125I]Alb, and brains were harvested 15 minutes after
[125I]Alb administration. Filipin, LY294002, histamine, verapamil, lido-
caine, monensin, and phenylarsine oxide were without effect on [125I]Alb
distribution, and none of the drugs affected the levels of [125I]Alb in serum
(data not shown). Significance (P . 0.05) indicated by asterisk.
Fig. 5. Effect of albumin (Alb) on the brain distribution of i.n. [125I]Lep.
Influence of albumin on the distribution among brain regions and to the blood
of i.n. administered [125I]Lep. Coadministration of [125I]Lep with 1% albumin
(1g/dl) resulted in lower levels of [125I]Lep appearing in the serum and cere-
bellum (CB) and a higher level appearing in hypothalamus (HT). Olfactory
bulb (OB) and whole brain (WB), but not hippocampus (HC), showed trends
(*P , 0.05; ***P , 0.001; t = 0.05 , P , 0.10) toward changes.
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Newton, 2013). More specifically, PMA can stimulate fluid
phase transcytosis, the same pathway that albumin uses to
cross endothelial cells (Guillot and Audus, 1990). Phenylarsine
oxide, which has effects onN-type Ca21 channel currents (Searl
and Silinsky, 2000), protein tyrosine phosphatases (Lohmann
et al., 2004), and phosphatidylinositol 4-kinase (Wiedemann
et al., 1998), an important step in the 4,5-biphosphate signal
pathway (Toker, 1998) that blocks receptor-mediated trans-
cytosis (Knutson et al., 1983), was without effect on i.n.
[125I]Alb uptake. The same was true of verapamil, the L- and
T-type Ca1 channel blocker (Bergson et al., 2011), which can
also inhibit P-glycoprotein, an ATP-dependent drug trans-
port protein (Schinkel, 1999). Albumin-binding proteins, such
as endothelial membrane–associated gp60 (albondin) (Schnitzer,
1992), use caveolae-dependent mechanisms to transport al-
bumin from peripheral blood vessel lumen to interstitium and
are inhibited by filipin (Schnitzer et al., 1994; Tiruppathi et al.,
1997), a cholesterol-binding agent that inhibits caveolae-
dependent transcytosis (Schnitzer et al., 1994). Pretreatment
with filipin did not affect [125I]Alb uptake here, indicating that
i.n. transport of albumin is not dependent on caveolae. The
phosphoinositide 3-kinase inhibitor LY294002 was also with-
out effect. Monensin, a compound that inhibits acidification of
intracellular organelles to prevent endocytosis and delivery
of macromolecules to lysosomes, had no effect on albumin
transport (Hastings et al., 1994). Lidocaine, which acts on
axons of sensory neurons to block the conduction of action
potentials by closing voltage-dependent Na1 channels, has an
attenuating effect on transport of materials in axons but had
no effect on albumin (Lavoie et al., 1989; Hiruma et al., 2008).
Also, vasogenic agents, such as histamine, did not increase
transport of albumin, despite increasing BBB permeability
(Stamatovic et al., 2008).
The consideration that albumin can be used to aid in the
uptake or targeting of other biologicals was confirmed in our
study with [125I]Lep. Leptin is a 16-kDa protein that has ef-
fects on both feeding and cognition (Pelleymounter et al., 1995;
Farr et al., 2006). As such, it has been considered for de-
velopment both as an anorectic and as a treatment of cognitive
impairments. However, the anorectic effects, although desir-
able in the treatment of obesity, would be a serious untoward
effect in the treatment of dementia. Here, albumin had several
beneficial effects on i.n. administered [125I]Lep uptake by the
brain. It decreased serum levels by supposedly retarding its
clearance from brain, it increased its uptake to the hypothal-
amus, which would supposedly enhance its potency as an
anorectic, and it decreased its uptake to nontarget sites, such
as the cerebellum and possibly the olfactory bulb and whole
brain.
In conclusion, we found that [125I]Alb was taken up by and
distributed throughout brain after i.n. administration, with
little [125I]Alb entering blood. [125I]Alb uptake was dose-
dependent and stimulated by PMA. Albumin influenced the
distribution of [125I]Lep, suggesting that i.n. albumin may be
used to deliver substances to the CNS. Our observation that
albumin readily reaches the brain after i.n. administration
could indicate new applications for albumin in designing
CNS-targeting drugs for the treatment of neurologic disease.
Authorship Contributions
Participated in research design: Banks, Salameh, Falcone,
Kabanov, Yi.
Conducted experiments: Salameh, Falcone, Yi, Cordy, Mortell.
Performed data analysis: Banks, Yi, Falcone, Salameh.
Wrote or contributed to the writing of the manuscript: Falcone,
Banks, Salameh, Yi, Kabanov.
References
Banks WA and Broadwell RD (1994) Blood to brain and brain to blood passage of
native horseradish peroxidase, wheat germ agglutinin, and albumin: pharmaco-
kinetic and morphological assessments. J Neurochem 62:2404–2419.
Banks WA, During MJ, and Niehoff ML (2004) Brain uptake of the glucagon-like
peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol
Exp Ther 309:469–475.
Banks WA, Morley JE, Niehoff ML, and Mattern C (2009) Delivery of testosterone to
the brain by intranasal administration: comparison to intravenous testosterone.
J Drug Target 17:91–97.
Benedict C, Frey WH, 2nd, Schiöth HB, Schultes B, Born J, and Hallschmid M (2011)
Intranasal insulin as a therapeutic option in the treatment of cognitive impair-
ments. Exp Gerontol 46:112–115.
Bergson P, Lipkind G, Lee SP, Duban M-E, and Hanck DA (2011) Verapamil block of
T-type calcium channels. Mol Pharmacol 79:411–419.
Charlton ST, Whetstone J, Fayinka ST, Read KD, Illum L, and Davis SS (2008)
Evaluation of direct transport pathways of glycine receptor antagonists and an
angiotensin antagonist from the nasal cavity to the central nervous system in the
rat model. Pharm Res 25:1531–1543.
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M,
Callaghan M, Tsai E, and Plymate SR, et al. (2012) Intranasal insulin therapy for
Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Arch Neurol 69:29–38.
Dhuria SV, Hanson LR, and Frey WH, 2nd (2010) Intranasal delivery to the central
nervous system: mechanisms and experimental considerations. J Pharm Sci 99:
1654–1673.
Elsadek B and Kratz F (2012) Impact of albumin on drug delivery: new applications
on the horizon. J Control Release 157:4–28.
Farr SA, Banks WA, and Morley JE (2006) Effects of leptin on memory processing.
Peptides 27:1420–1425.
Frey WH, II (2002) Bypassing the blood-brain barrier to deliver therapeutic agents to
the brain and spinal cord. J Drug Deliv Sci Technol 2:46–49.
Glowinski J and Iversen LL (1966) Regional studies of catecholamines in the rat
brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in
various regions of the brain. J Neurochem 13:655–669.
Greenwood FC, Hunter WM, and Glover JS (1963) The preparation of 131I-labelled
human growth hormone of high specific radioactivity. Biochem J 89:114–123.
Guillot FL and Audus KL (1990) Angiotensin peptide regulation of fluid-phase en-
docytosis in brain microvessel endothelial cell monolayers. J Cereb Blood Flow
Metab 10:827–834.
Hastings RH, Wright JR, Albertine KH, Ciriales R, and Matthay MA (1994) Effect of
endocytosis inhibitors on alveolar clearance of albumin, immunoglobulin G, and
SP-A in rabbits. Am J Physiol 266:L544–L552.
Hiruma H, Shimizu K, Takenami T, Sugie H, and Kawakami T (2008) Effects of
clonidine on lidocaine-induced inhibition of axonal transport in cultured mouse
dorsal root ganglion neurones. Br J Anaesth 101:659–665.
Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, and Benveniste H (2013)
Brain-wide pathway for waste clearance captured by contrast-enhanced MRI.
J Clin Invest 123:1299–1309.
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE,
Deane R, Goldman SA, et al. (2012) A paravascular pathway facilitates CSF flow
through the brain parenchyma and the clearance of interstitial solutes, including
amyloid beta. Sci Transl Med 4:147ra111.
Knutson VP, Ronnett GV, and Lane MD (1983) Rapid, reversible internalization of
cell surface insulin receptors: correlation with insulin-induced down-regulation.
J Biol Chem 258:12139–12142.
Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and
nanoparticles. J Control Release 132:171–183.
Kratz F and Elsadek B (2012) Clinical impact of serum proteins on drug delivery.
J Control Release 161:429–445.
Lavoie PA, Khazen T, and Filion PR (1989) Mechanisms of the inhibition of fast
axonal transport by local anesthetics. Neuropharmacology 28:175–181.
Lochhead JJ and Thorne RG (2012a) Intranasal delivery of biologics to the central
nervous system. Adv Drug Deliv Rev 64:614–628.
Lohmann C, Krischke M, Wegener J, and Galla HJ (2004) Tyrosine phosphatase
inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-
dependent and -independent pathways. Brain Res 995:184–196.
Migliore MM, Vyas TK, Campbell RB, Amiji MM, and Waszczak BL (2010) Brain
delivery of proteins by the intranasal route of administration: a comparison of
cationic liposomes versus aqueous solution formulations. J Pharm Sci 99:
1745–1761.
Nonaka N, Farr SA, Nakamachi T, Morley JE, Nakamura M, Shioda S, and Banks
WA (2012) Intranasal administration of PACAP: uptake by brain and regional
brain targeting with cyclodextrins. Peptides 36:168–175.
Pardridge WM, Eisenberg J, and Cefalu WT (1985) Absence of albumin receptor on
brain capillaries in vivo or in vitro. Am J Physiol 249:E264–E267.
Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, and Collins
F (1995) Effects of the obese gene product on body weight regulation in ob/ob mice.
Science 269:540–543.
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR,
Cherrier MM, Schellenberg GD, and Frey WH, 2nd, et al. (2008) Intranasal insulin
administration dose-dependently modulates verbal memory and plasma amyloid-
beta in memory-impaired older adults. J Alzheimers Dis 13:323–331.
Brain Uptake of Intranasal Albumin 59
Schinkel AH (1999) P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug
Deliv Rev 36:179–194.
Schnitzer JE (1992) gp60 is an albumin-binding glycoprotein expressed by con-
tinuous endothelium involved in albumin transcytosis. Am J Physiol 262:
H246–H254.
Schnitzer JE, Oh P, Pinney E, and Allard J (1994) Filipin-sensitive caveolae-
mediated transport in endothelium: reduced transcytosis, scavenger endocytosis,
and capillary permeability of select macromolecules. J Cell Biol 127:1217–1232.
Schulz C, Paulus K, Jöhren O, and Lehnert H (2012) Intranasal leptin reduces appetite
and induces weight loss in rats with diet-induced obesity (DIO). Endocrinology 153:
143–153.
Searl TJ and Silinsky EM (2000) The phosphatidylinositol 4-kinase inhibitor phe-
nylarsine oxide blocks evoked neurotransmitter release by reducing calcium entry
through N-type calcium channels. Br J Pharmacol 130:418–424.
Stamatovic SM, Keep RF, and Andjelkovic AV (2008) Brain endothelial cell-cell
junctions: how to “open” the blood brain barrier. Curr Neuropharmacol 6:179–192.
Thorne RG, Pronk GJ, Padmanabhan V, and Frey WH, 2nd (2004) Delivery of
insulin-like growth factor-I to the rat brain and spinal cord along olfactory and
trigeminal pathways following intranasal administration. Neuroscience 127:
481–496.
Tiruppathi C, Song W, Bergenfeldt M, Sass P, and Malik AB (1997) Gp60 activation
mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent
pathway. J Biol Chem 272:25968–25975.
Toker A (1998) The synthesis and cellular roles of phosphatidylinositol 4,5-bisphos-
phate. Curr Opin Cell Biol 10:254–261.
Veening JG and Olivier B (2013) Intranasal administration of oxytocin: behavioral
and clinical effects, a review. Neurosci Biobehav Rev 37:1445–1465.
Wiedemann C, Schafer T, Burger MM and Sihra TS (1998) An essential role for
a small synaptic vesicle-associated phosphatidylinositol 4-kinase in neurotrans-
mitter release. J Neurosci 18:5594–5602.
Wu-Zhang AX and Newton AC (2013) Protein kinase C pharmacology: refining the
toolbox. Biochem J 452:195–209.
Address correspondence to: William A. Banks, 1660 S. Columbian Way,
810A/Bldg 1, VAPSHCS, Seattle, WA 98108. E-mail: wabanks1@uw.edu
60 Falcone et al.
